Pharmaceutical Commerce

Featured Content

Pharmaceutical Commerce - August 2025

Click here to read the articles and view the interactive digital edition

Pharma Wholesalers: Looking for Growth

Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well.

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

340B Litigation and the Path Toward Transparent Drug Discount Programs

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

Asembia 2025: The Role of Face-to-Face Connection in Pharma Commercialization

April 28, 2025

Blake Powers, CEO, Medigi, discusses how face-to-face collaboration and streamlined commercialization strategies are helping life sciences companies deliver therapies more efficiently to patients.

Why Distractions Are Detrimental to Business

April 28, 2025

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes the uneasiness behind regulatory complications.

Pharma Pulse 4/28/25: US Pharma Tariffs Would Raise US Drug Costs by $51 Billion Annually, Report Finds, How the Tariffs Expose Vulnerabilities in the Pharma Pipeline

April 28, 2025

FDA Approves Additional Manufacturing Plant for Ferring’s Adstiladrin

April 28, 2025

The company’s branded form of nadofaragene firadenovec-vncg will also be produced at a hub in Parsippany, NJ.

Fast-Tracking the Future

April 25, 2025

Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.

Will Moving Drug Production to the United States Help or Hurt Patients?

April 25, 2025

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, explains what the mindset be for companies who are just starting the reshoring process.

Pharma Pulse 4/25/25: Roche in ‘Very, Very Good Position’ To Weather Trump Tariffs but M&A May Suffer, Thermo Fisher to Invest Addlitional $2 Billion In US To Boost Manufacturing

April 25, 2025

PCI to Purchase Full Stake in Ajinomoto Althea

April 24, 2025

The deal for the San Diego hub provides the CDMO with its first-ever North American manufacturing location for prefilled syringes and cartridges.

The Future of Specialty Medicine

April 24, 2025

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes potential availability challenges brought on by supply chain obstacles.

Pharma Pulse 4/24/25: Understanding True Meaning of Risk in Clinical Trial Operations, European Pharma Companies Push for Higher Drug Prices Amid US Tariff Threats

April 24, 2025